Products and Pipeline
Revance is a fast-growing global aesthetics and skincare company focused on providing innovative aesthetics and market-leading skincare offerings throughout every stage of life.
Aesthetics
DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection, the first and only peptide formulated neuromodulator with long-lasting results, is FDA approved for the temporary improvement of moderate to severe frown lines (glabellar lines) in adults.
The Teoxane RHA® Collection uses the patented Preserved Network Technology, which creates unique rheological gel properties with the highest stretch and dynamic strength of all hyaluronic acid (HA) fillers on the market. These are the only HA fillers approved by the FDA for moderate to severe dynamic facial lines, wrinkles, folds (RHA® 2, RHA® 3, RHA® 4), perioral rhytids (RHA Redensity®), and lips (RHA® 3).¹⁻²
SkinPen® Precision* is the #1 microneedling brand§ in the U.S., clinically proven to improve the appearance of neck wrinkles for Fitzpatrick skin types II – IV and facial acne scars for people age 22 and above in all skin types.
CONSUMER SKINCARE†
PanOxyl is The Acne Authority™ known for providing dermatologist-recommended solutions to cleanse, manage, and moisturize acne-prone skin.
StriVectin pioneers clinically proven skincare that strengthens and transforms skin health for the long term. Powered by science, innovation and our exclusive NIA-114® technology, we create solutions that deliver real, lasting results—helping skin look and act younger, for life.
Blue Lizard simplifies sun protection with dermatologist and pediatrician-trusted mineral sunscreen lotions, sprays, and sticks to help everyone be fearless in the sun.
Sarna is the #1 dermatologist recommended topical anti-itch brand‡ delivering high-quality ingredients and superior attention to sensitive, steroid-free product formulations.
Zeasorb is a dermatologist-recommended brand that helps you get back in the zone with high-performing powders to help treat excess moisture, athlete’s foot, and jock itch.
Desenex provides lasting relief for hardworking feet with prescription-strength powder and cream formulas targeting athlete’s foot.
Keri gives your skin a daily dose of moisture with skin-nourishing products that are backed by over 50 years of experience.
THERAPEUTICS
*SkinPen® Precision and BIOJUVE® are owned by Crown Aesthetics, a Revance company.
†All products under consumer skincare portfolio are owned by Crown Laboratories, Inc., a Revance company.
‡Data on File
§2024 Crown Aesthetics HCP Market Tracker, September 2024.
REFERENCES
1 – RHA® DIRECTIONS FOR USE, 2025.
2 – Faivre J, Gallet M, Tremblais E, Trévidic P, Bourdon F. Dermatol Surg. 2021;47(5):159-167.
IMPORTANT SAFETY INFORMATION for DAXXIFY® (daxibotulinumtoxinA-Ianm) for injection
Indications
(daxibotulinumtoxinA-lanm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients and for the treatment of cervical dystonia in adults.
WARNING: DISTANT SPREAD OF TOXIN EFFECT The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than cervical dystonia and glabellar lines.
IMPORTANT SAFETY INFORMATION
Contraindications
DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).
Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.
The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.
Adverse Reactions
The most commonly observed adverse reactions are:
Glabeller lines (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).
Cervical Dystonia (≥5%): headache (9%), injection site pain (8%), injection site erythema (5%), muscular weakness (5%), and upper respiratory tract infection (5%).
Drug Interactions
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.
Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.
Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.
To report side effects associated with DAXXIFY®, please visit safety.revance.com, or call 1-877-373-8669. You may also report side effects to the FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch
DAXI-004726
